UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study

  • Karim Makdoumi
  • Jes Mortensen
  • Omid Sorkhabi
  • Bo-Eric Malmvall
  • Sven Crafoord
Cornea

Abstract

Background

The aim of this work as to investigate the photochemical interaction used in corneal crosslinking (CXL) as the primary therapy for bacterial keratitis.

Methods

A prospective non-randomized study was conducted including 16 patients with a clinical diagnosis of bacterial keratitis. No patient had any prior antibiotic treatment for the current infection. Photography and microbial culturing of the infected cornea were performed. Riboflavin was topically administered for 20 min and ultraviolet light (UVA) exposure settings for treatment of keratoconus were used. After the procedure, clinical examinations were done at least once daily until signs of improvement had been established. The frequency of examinations was thereafter reduced. Antibiotic therapy was initiated if infectious progression was suspected. The trial was registered at ISCRTN.org (no: 21432643).

Results

All eyes responded to the photochemical treatment with improvement in symptoms and signs of reduced inflammation. Epithelial healing was achieved in all cases. Antibiotic administration was necessary in two cases. One patient required a human amniotic membrane transplant.

Conclusions

This trial illustrates that photosensitization of riboflavin using UVA at 365 nm has the potential to induce healing in patients with microbial keratitis. The results from the treatment of these 16 patients with corneal ulcers indicate that UVA-riboflavin photochemical therapy merits a controlled study in order to assess its efficacy and safety compared to antibiotics.

Keywords

UV UVA Ultraviolet Riboflavin CXL Keratitis Pilot study 

References

  1. 1.
    Keay L, Edwards K, Naduvilath T, Taylor HR, Snibson GR, Forde K, Stapleton F (2006) Microbial keratitis predisposing factors and morbidity. Ophthalmology 113:109–116PubMedCrossRefGoogle Scholar
  2. 2.
    Bourcier T, Thomas F, Borderie V, Chaumeil C, Laroche L (2003) Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol 87:834–838PubMedCrossRefGoogle Scholar
  3. 3.
    Wong T, Ormonde S, Gamble G, McGhee CN (2003) Severe infective keratitis leading to hospital admission in New Zealand. Br J Ophthalmol 87:1103–1108PubMedCrossRefGoogle Scholar
  4. 4.
    McLeod SD, LaBree LD, Tayyanipour R, Flowers CW, Lee PP, McDonnell PJ (1995) The importance of initial management in the treatment of severe infectious corneal ulcers. Ophthalmology 102:1943–1948PubMedGoogle Scholar
  5. 5.
    Ibrahim YW, Boase DL, Cree IA (2009) Epidemiological characteristics, predisposing factors and microbiological profiles of infectious corneal ulcers: the Portsmouth corneal ulcer study. Br J Ophthalmol 93:1319–1324PubMedCrossRefGoogle Scholar
  6. 6.
    Green M, Apel A, Stapleton F (2008) Risk factors and causative organisms in microbial keratitis. Cornea 27:22–27PubMedCrossRefGoogle Scholar
  7. 7.
    Saeed A, D'Arcy F, Stack J, Collum LM, Power W, Beatty S (2009) Risk factors, microbiological findings, and clinical outcomes in cases of microbial keratitis admitted to a tertiary referral center in Ireland. Cornea 28:285–292PubMedCrossRefGoogle Scholar
  8. 8.
    Jeng BH, Gritz DC, Kumar AB, Holsclaw DS, Porco TC, Smith SD, Whitcher JP, Margolis TP, Wong IG (2010) Epidemiology of ulcerative keratitis in Northern California. Arch Ophthalmol 128:1022–1028PubMedCrossRefGoogle Scholar
  9. 9.
    McGowan JE Jr (2006) Resistance in nonfermenting Gram-negative bacteria: multidrug resistance to the maximum. Am J Med 119:S29–S36, discussion S62-70PubMedCrossRefGoogle Scholar
  10. 10.
    Harris AD, McGregor JC, Furuno JP (2006) What infection control interventions should be undertaken to control multidrug-resistant Gram-negative bacteria? Clin Infect Dis 43(Suppl 2):S57–S61PubMedCrossRefGoogle Scholar
  11. 11.
    Rice LB (2007) Emerging issues in the management of infections caused by multidrug-resistant Gram-negative bacteria. Cleve Clin J Med 74(Suppl 4):S12–S20PubMedCrossRefGoogle Scholar
  12. 12.
    Falagas ME, Bliziotis IA (2007) Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 29:630–636PubMedCrossRefGoogle Scholar
  13. 13.
    Souli M, Galani I, Giamarellou H (2008) Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 13(47). pii:19045Google Scholar
  14. 14.
    Bertino JS (2009) Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin Ophthalmol 3:507–521PubMedCrossRefGoogle Scholar
  15. 15.
    Betanzos-Cabrera G, Juarez-Verdayes MA, Gonzalez-Gonzalez G, Cancino-Diaz ME, Cancino-Diaz JC (2009) Gatifloxacin, moxifloxacin, and balofloxacin resistance due to mutations in the gyrA and parC genes of Staphylococcus epidermidis strains isolated from patients with endophthalmitis, corneal ulcers and conjunctivitis. Ophthalmic Res 42:43–48PubMedCrossRefGoogle Scholar
  16. 16.
    Ramos-Esteban JC, Bamba S, Jeng BH (2008) Treatment of multidrug-resistant Flavobacterium indologenes keratitis with trimethoprim-sulfamethoxazole. Cornea 27:1074–1076PubMedCrossRefGoogle Scholar
  17. 17.
    Moshirfar M, Meyer JJ, Espandar L (2007) Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusis. J Cataract Refract Surg 33:1978–1981PubMedCrossRefGoogle Scholar
  18. 18.
    de la Cruz J, Behlau I, Pineda R (2007) Atypical mycobacteria keratitis after laser in situ keratomileusis unresponsive to fourth-generation fluoroquinolone therapy. J Cataract Refract Surg 33:1318–1321PubMedCrossRefGoogle Scholar
  19. 19.
    Wollensak G (2006) Crosslinking treatment of progressive keratoconus: new hope. Curr Opin Ophthalmol 17:356–360PubMedCrossRefGoogle Scholar
  20. 20.
    Caporossi A, Mazzotta C, Baiocchi S, Caporossi T (2010) Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study. Am J Ophthalmol 149:585–593PubMedCrossRefGoogle Scholar
  21. 21.
    Wollensak G, Spoerl E, Seiler T (2003) Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol 135:620–627PubMedCrossRefGoogle Scholar
  22. 22.
    Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE (2008) Collagen crosslinking with riboflavin and ultraviolet—a light in keratoconus: long-term results. J Cataract Refract Surg 34:796–801PubMedCrossRefGoogle Scholar
  23. 23.
    Wittig-Silva C, Whiting M, Lamoureux E, Lindsay RG, Sullivan LJ, Snibson GR (2008) A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. J Refract Surg 24:S720–S725PubMedGoogle Scholar
  24. 24.
    Vinciguerra P, Camesasca FI, Albe E, Trazza S (2009) Corneal collagen cross-linking for ectasia after excimer laser refractive surgery: 1-year results. J Refract Surg: 1–12Google Scholar
  25. 25.
    Mazzotta C, Traversi C, Baiocchi S, Sergio P, Caporossi T, Caporossi A (2006) Conservative treatment of keratoconus by riboflavin-uva-induced cross-linking of corneal collagen: qualitative investigation. Eur J Ophthalmol 16:530–535PubMedGoogle Scholar
  26. 26.
    Ashwin PT, McDonnell PJ (2010) Collagen cross-linkage: a comprehensive review and directions for future research. Br J Ophthalmol 94:965–970PubMedCrossRefGoogle Scholar
  27. 27.
    Schnitzler E, Sporl E, Seiler T (2000) Irradiation of cornea with ultraviolet light and riboflavin administration as a new treatment for erosive corneal processes, preliminary results in four patients. Klin Monbl Augenheilkd 217:190–193PubMedCrossRefGoogle Scholar
  28. 28.
    Iseli HP, Thiel MA, Hafezi F, Kampmeier J, Seiler T (2008) Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea 27:590–594PubMedCrossRefGoogle Scholar
  29. 29.
    Micelli Ferrari T, Leozappa M, Lorusso M, Epifani E, Micelli Ferrari L (2009) Escherichia coli keratitis treated with ultraviolet A/riboflavin corneal cross-linking: a case report. Eur J Ophthalmol 19:295–297PubMedGoogle Scholar
  30. 30.
    Moren H, Malmsjo M, Mortensen J, Ohrstrom A (2010) Riboflavin and ultraviolet a collagen crosslinking of the cornea for the treatment of keratitis. Cornea 29:102–104PubMedCrossRefGoogle Scholar
  31. 31.
    Khan YA, Kashiwabuchi RT, Martins SA, Castro-Combs JM, Kalyani S, Stanley P, Flikier D, Behrens A (2011) Riboflavin and ultraviolet light A therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis: report of 3 cases. Ophthalmology 118:324–331Google Scholar
  32. 32.
    Makdoumi K, Mortensen J, Crafoord S (2010) Infectious keratitis treated with corneal crosslinking. Cornea 29:1353–1358PubMedCrossRefGoogle Scholar
  33. 33.
    Martins SA, Combs JC, Noguera G, Camacho W, Wittmann P, Walther R, Cano M, Dick J, Behrens A (2008) Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci 49:3402–3408PubMedCrossRefGoogle Scholar
  34. 34.
    Schrier A, Greebel G, Attia H, Trokel S, Smith EF (2009) In vitro antimicrobial efficacy of riboflavin and ultraviolet light on Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, and Pseudomonas aeruginosa. J Refract Surg 25:S799–S802PubMedCrossRefGoogle Scholar
  35. 35.
    Makdoumi K, Backman A, Mortensen J, Crafoord S (2010) Evaluation of antibacterial efficacy of photo-activated riboflavin using ultraviolet light (UVA). Graefes Arch Clin Exp Ophthalmol 248:207–212PubMedCrossRefGoogle Scholar
  36. 36.
    Goodrich RP, Edrich RA, Li J, Seghatchian J (2006) The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 35:5–17PubMedCrossRefGoogle Scholar
  37. 37.
    Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP (2004) Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion (Paris) 44:877–885CrossRefGoogle Scholar
  38. 38.
    Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Mendez J, Reddy H, Goodrich R (2006) Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 90:85–91PubMedCrossRefGoogle Scholar
  39. 39.
    Cardo LJ, Salata J, Mendez J, Reddy H, Goodrich R (2007) Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 37:131–137PubMedCrossRefGoogle Scholar
  40. 40.
    Tonnetti L, Proctor MC, Reddy HL, Goodrich RP, Leiby DA (2010) Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion (Paris) 50:1019–1027CrossRefGoogle Scholar
  41. 41.
    Wollensak G, Spoerl E, Wilsch M, Seiler T (2004) Keratocyte apoptosis after corneal collagen cross-linking using riboflavin/UVA treatment. Cornea 23:43–49PubMedCrossRefGoogle Scholar
  42. 42.
    Kohlhaas M, Spoerl E, Schilde T, Unger G, Wittig C, Pillunat LE (2006) Biomechanical evidence of the distribution of cross-links in corneas treated with riboflavin and ultraviolet A light. J Cataract Refract Surg 32:279–283PubMedCrossRefGoogle Scholar
  43. 43.
    Dhaliwal JS, Kaufman SC (2009) Corneal collagen cross-linking: a confocal, electron, and light microscopy study of eye bank corneas. Cornea 28:62–67PubMedCrossRefGoogle Scholar
  44. 44.
    Spoerl E, Wollensak G, Dittert DD, Seiler T (2004) Thermomechanical behavior of collagen-cross-linked porcine cornea. Ophthalmologica 218:136–140PubMedCrossRefGoogle Scholar
  45. 45.
    Wollensak G, Spoerl E, Seiler T (2003) Stress-strain measurements of human and porcine corneas after riboflavin-ultraviolet-A-induced cross-linking. J Cataract Refract Surg 29:1780–1785PubMedCrossRefGoogle Scholar
  46. 46.
    Spoerl E, Wollensak G, Seiler T (2004) Increased resistance of crosslinked cornea against enzymatic digestion. Curr Eye Res 29:35–40PubMedCrossRefGoogle Scholar
  47. 47.
    Wang F (2008) UVA/riboflavin-induced apoptosis in mouse cornea. Ophthalmologica 222:369–372PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Karim Makdoumi
    • 1
  • Jes Mortensen
    • 1
    • 2
  • Omid Sorkhabi
    • 2
  • Bo-Eric Malmvall
    • 3
    • 4
  • Sven Crafoord
    • 1
  1. 1.Department of OphthalmologyÖrebro University HospitalÖrebroSweden
  2. 2.Department of OphthalmologyRyhov County HospitalJönköpingSweden
  3. 3.Department of Infectious MedicineRyhov County Hospital, Futurum, the Academy of HealthJönköpingSweden
  4. 4.Department of Infectious Medicine, Institution of Clinical and Experimental MedicineUniversity of LinköpingLinköpingSweden

Personalised recommendations